Reuters logo
BRIEF-Exelixis, Ipsen post results from advanced renal cell carcinoma study
2016年6月6日 / 中午11点47分 / 1 年前

BRIEF-Exelixis, Ipsen post results from advanced renal cell carcinoma study

June 6 (Reuters) - Exelixis Inc :

* Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CABOMETYX(tm) (cabozantinib) tablets in advanced renal cell carcinoma at 2016 ASCO annual meeting

* Additional data from pivotal meteor trial underscore clinically meaningful benefit of CABOMETYX across subgroups of patients Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below